Hemispherx Biopharma Announces Filing a New Drug Application in Argentina for Ampligen to Treat Chronic Fatigue Syndrome

Hemispherx Biopharma, Inc. HEB, announced that it has submitted a new drug application to ANMAT (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica), the agency responsible for the national regulation of drugs, foods and medical technology in Argentina, under the ANMAT's Orphan Drug regulations.